Argatroban

Argatroban
Clinical data
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability100% (intravenous)
Protein binding54%
Metabolismhepatic
Elimination half-life39 and 51 minutes
Identifiers
  • (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-
    [[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]
    sulfonylamino]pentanoyl]-4-methyl-piperidine-2-
    carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.166.378 Edit this at Wikidata
Chemical and physical data
FormulaC23H36N6O5S
Molar mass508.64 g·mol−1
3D model (JSmol)
  • O=C(O)[C@@H]3N(C(=O)C(NS(=O)(=O)c1cccc2c1NCC(C2)C)CCC/N=C(\N)N)CC[C@@H](C)C3
  • InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1 ☒N
  • Key:KXNPVXPOPUZYGB-IOVMHBDKSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.[3] In 2000, argatroban was licensed by the US Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in people with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in people who have HIT or are at risk for developing it. In 2012, it was approved by the UK Medicines and Healthcare products Regulatory Agency for anticoagulation in people with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.[4]

Argatroban is given intravenously and drug plasma concentrations reach steady state in 1–3 hours.[5] Argatroban is metabolized in the liver and has a half-life of about 50 minutes. It is monitored by PTT. Because of its hepatic metabolism, it may be used in patients with renal dysfunction. (This is in contrast to lepirudin, a direct thrombin inhibitor that is primarily renally cleared).

  1. ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 13 July 2024.
  2. ^ "Argatroban injection, solution". DailyMed. Retrieved 10 June 2021.
  3. ^ Di Nisio M, Middeldorp S, Buller HR (2005). "Direct thrombin inhibitors". N Engl J Med. 353 (10): 1028–40. doi:10.1056/NEJMra044440. PMID 16148288.
  4. ^ "UK launch for Mitsubishi's blood thinner Exembol". 3 July 2012.
  5. ^ Dhillon, S (2009). "Argatroban: A Review of its Use in the Management of Heparin-Induced Thrombocytopenia". Am J Cardiovasc Drugs. 9 (4): 261–82. doi:10.2165/1120090-000000000-00000. PMID 19655821.